Neuralink Captures Wall Street’s Eye, Sparks Debate Over Brain Interfaces and Future “Neuro Elite”

The brain-computer interface (BCI) field is advancing rapidly—faster than the average person can keep up with. As the technology progresses, Wall Street is also turning its attention toward areas of deep tech and bioscience, including emergent research into BCIs.

A new Morgan Stanley research report issued on October 8, titled Neuralink: AI in your brAIn, places its focus on Elon Musk’s innovative—and at times controversial—BCI company. The report argues that Musk and his BCI team at Neuralink are at the forefront of a larger technological shift that society may not be ready for: one with staggering implications that could ultimately impact everything from healthcare to gaming, defense, investing, and society at large.

“As AI moves into the physical world through expressions ranging from robotaxis to humanoids and autonomous weapons systems, we recommend paying closer attention to developments in brain-computer interface,” a portion of the paper states, under a section titled “Prometheus Shrugged.”

The report’s overall thesis is clear: BCIs are moving from speculative science to an investable opportunity—or, in layman’s terms, from “science fiction” to “science fact.” One major factor driving this rapid acceleration is artificial intelligence. The report warns that “the ability for human beings to ‘keep up’ and communicate with the AI apparatus may deteriorate at an exponential rate,” noting that “one of Elon Musk’s many goals in founding Neuralink is to ‘give humanity a chance’ to keep up with AGI.”

Neuralink has captured the attention of the nascent BCI market, most notably with the development of “The Link,” the company’s primary BCI technology, and its 2024 use with Noland Arbaugh, the first human to receive a Neuralink device. The company’s future goals include enabling thought-controlled computing, prosthetics, and even restored vision. For investors, Morgan Stanley estimates the total U.S. healthcare market at $400 billion—a figure expected to grow as BCI applications move into the global market.

Healthcare as the ‘Back Door’

Like many emerging deep-tech applications, BCI development typically begins in healthcare—and for good reason. Patients suffering from ALS, paralysis, and other life-altering neurological conditions are among the earliest beneficiaries. For patients like Ian Burkhart, founder of the BCI Pioneers Coalition, and Noland Arbaugh, clinical trial participation has proven life-changing, helping them regain a sense of purpose and contribution to society.

Neuralink has identified a pool of early candidates eager for participation in trials with The Link, labeled under the Telepathy brand, which the company says will drive “ambitious development” in the BCI marketplace—perhaps even faster than anticipated. Neuralink’s Telepathy allows paralyzed patients to control devices through thought, while its second major healthcare initiative, Blindsight, aims to restore vision through stimulation of the visual cortex.

As of September 2025, twelve patients had received implants, with more than 10,000 on the waitlist. Morgan Stanley notes that one patient reportedly logs over 100 hours per week on the device—suggesting early signs of “sticky” daily integration. While the healthcare implications are profound, investors see even greater potential gains in the years ahead.

“BCIs will likely enter society first through medical indications—stroke, spinal cord injury, neurodegenerative disease—so equitable access must be built into early reimbursement and regulatory frameworks,” said Carolina Aguilar, CEO and Co-founder of INBRAIN Neuroelectronics, in an email to The Debrief.

“Otherwise, we risk creating a two-tiered system where only those who can pay benefit from transformative neurotechnology,” said Aguilar, who spoke with The Debrief regarding the impacts of such technologies in the years ahead and was not involved with the publication of the recent report. “Transparency, insurance inclusion, and clear medical necessity standards will be key.”

But the ethical implications for society remain pressing. The report cautions that “while the topic of many sci-fi books and films, brain-computer interfaces are the new frontier for humanity and will entail a host of moral, ethical, and legal-regulatory considerations along the way.”

MIND ACT Policy

On September 24, Senate Majority Leader Chuck Schumer, along with Senators John Cornyn and Ron Wyden, proposed legislation to regulate BCIs, requesting the FTC to closely examine the policy for long-term use. Formally named the Management of Individuals’ Neural Data Act of 2025 (MIND Act), it mandates OSTP and OMB to create guidelines and a framework to address ethical concerns, along with promoting safety and privacy in the U.S. Congress. The Act was created to address concerns and risks this technology could have if individuals are not protected under U.S. Law.

Concerns about how BCIs could influence ideas, memories, and emotions have become central to recent policy discussions. Global law firm Cooley LLP, which represents several major technology and life sciences companies, noted in a recent post regarding the MIND Act that the technologies in question “can not only detect brain activity, but they can also stimulate the brain, and therefore have an impact on the brain.

“Brain stimulation is used, for example, to treat depression,” the posting reads. “But it can also theoretically be used to cause a person to feel an emotion that they did not feel absent the stimulation.”

The Cooley Alert posting also referenced a famous 1960s experiment by Spanish researcher Dr. José Delgado, who used a remote control to stimulate a bull’s brain and stop its charge mid-run, resuming once the stimulation ceased. “One can imagine,” the firm wrote, “how a technology like that could be used in warfare, sports, or a host of other use cases.”

Additionally, the MIND Act references broader concerns, including “mind and behavior manipulation, monetization of neural data, neuromarketing, erosion of personal autonomy, discrimination and exploitation, and surveillance.”

“Policy initiatives like the MIND Policy Act are essential to get ahead of rapid innovation,” Aguilar told The Debrief. “They can establish guardrails for data privacy, informed consent, and interoperability—while ensuring that patients, not corporations, ultimately own their neural data.

“Regulation shouldn’t stifle innovation, but it must protect autonomy, accessibility, and safety as BCIs move from the lab into daily life,” she added.

“Legislation like the MIND Policy Act is a positive step toward creating clear guardrails for privacy, data ownership, and ethical standards in neurotechnology,” said Kurt Haggstrom, Chief Commercial Officer of Synchron, a BCI company whose technologies aim to assist individuals with limited mobility.

“Responsible oversight builds the public trust that medical innovation depends on—and that’s essential for bringing BCIs safely into healthcare systems,” Haggstrom told The Debrief in an email. “Our CEO, Dr. Tom Oxley, serves on the World Economic Forum’s Neurotechnology Governance Committee, where he’s helping shape the global dialogue on how to advance these technologies safely, ethically, and inclusively,” he added.

Presently, Musk’s expanding network of companies is increasingly interconnected, and Neuralink’s role within that ecosystem is becoming more defined. While current crossover remains limited, future integration appears inevitable. Tesla’s hardware and sensor platforms could feed data to xAI models, while Neuralink’s BCIs may eventually enable direct AI-human symbiosis and even help train xAI systems using neural input.

Does this mean that technologies like mind-controlled cars are closer than we think? Aguilar said that while we’re moving in that direction, she thinks we’re still a few years away from the realization of such technologies.

“At present, BCIs can translate simple, low-bandwidth neural signals into actions,” Aguilar said, “like moving a cursor or selecting a target—but full manual control of complex systems such as cars or humanoid robots requires far higher reliability, data throughput, and safety validation.

“The realistic short-term path is shared control: the BCI communicates intent, while autonomous systems handle execution,” Aguilar says. “Over time, as decoding improves and autonomy advances, those boundaries will blur—but ‘mind-only operation is still years away.”

Neuralink has reportedly already begun planning to use Tesla’s Optimus robots to test mind-controlled limbs, with long-term plans for full-body prosthetic integration. Although no formal collaboration currently exists between xAI and Neuralink, Musk’s close coordination across ventures—along with shared leadership figures like Jared Birchall, who serves as co-CFO of both companies—suggests a unified trajectory toward merging human and machine intelligence.

From Healthcare to Superpowers

Healthcare is at the forefront of BCI technology—but it may soon take a backseat to Neuralink’s more ambitious goals. Musk has openly described future aims of enhancing human capabilities, ranging from super-vision in infrared and ultraviolet to philosophical objectives like expanding human consciousness and uploading memories—creating a “saved version of yourself” or even “uploading your memory into a robot body.”

Ultimately, Neuralink hopes to achieve “symbiosis with AI,” allowing humans to evolve alongside artificial intelligence rather than be overtaken by it. Musk, it seems, is in pursuit of digital immortality.

Competition Heats Up

The report also reviews the broader BCI landscape, referencing innovative companies like Synchron, which is advancing a less invasive “Stentrode” implant currently in human trials. Precision Neuroscience, founded by former Neuralink co-founder Benjamin Rapoport, is developing a minimally invasive “Layer 7” cortical interface. Paradromics and Merge Labs are likewise advancing their own approaches.

Meanwhile, Chinese state-backed initiatives aim to produce “two to three globally influential leaders” in the field by 2030. With competition intensifying, it remains unclear which companies will focus primarily on healthcare applications versus consumer integration.

Rise of the “Neuro-Elite”: Risks and Realities

In the company’s report, it cautions that the road ahead will be challenging, referencing risks including invasive implantation procedures, electrode degradation, and the potential hacking of neural data—all of which raise profound global ethical concerns. Perhaps the most pressing social risk is the potential emergence of a “neuro-elite” class of individuals, which the report envisions as a small group of wealthy individuals who can afford implants, a development which could potentially deepen social inequality.

“The first generation of BCIs is focused on restoration, not enhancement—helping people with paralysis communicate or move again,” Aguilar told The Debrief. “Enhancement could follow, but only after we’ve proven safety, reliability, and durability over many years.”

“Under medical device regulation, the benefit needs to largely outweigh the risk,” she adds. “Any path toward ‘cognitive upgrades’ will likely start with narrow use cases, such as decision-support tools or neurofeedback for attention and learning. We’re still in the early innings.” 

Overall, while no investment recommendation is provided in the report, citing limited information that is publicly accessible to private companies, Morgan Stanley nonetheless advises consumers and investors to recognize that BCIs are moving rapidly from the pages of science fiction into financial portfolios.

At the forefront of that progress, Neuralink appears to be preparing humanity for a future where the boundary between human and machine continues to become less well-defined, and eventually may all but disappear.

Chrissy Newton is a PR professional and the founder of VOCAB Communications. She currently appears on The Discovery Channel and Max and hosts the Rebelliously Curious podcast, which can be found on YouTube and on all audio podcast streaming platforms. Follow her on X: @ChrissyNewton, Instagram: @BeingChrissyNewton, and chrissynewton.com.